312 related articles for article (PubMed ID: 28238096)
21. PML-RARA transcript levels at the end of induction therapy are associated with prognosis in non-high-risk acute promyelocytic leukaemia with all-trans retinoic acid plus arsenic in front-line therapy: long-term follow-up of a single-centre cohort study.
Tang FF; Lu SY; Zhao XS; Qin YZ; Liu XH; Jia JS; Wang J; Gong LZ; Jiang Q; Zhao T; Shi HX; Chang YJ; Huang XJ; Jiang H
Br J Haematol; 2021 Dec; 195(5):722-730. PubMed ID: 34405393
[TBL] [Abstract][Full Text] [Related]
22. [Can As2O3 improve the prognosis of childhood acute promyelocytic leukemia?--A single center experience].
Cheng YF; Zhang LP; Lu AD; Liu GL; Wang B; Liu CF
Zhonghua Xue Ye Xue Za Zhi; 2008 Jul; 29(7):454-8. PubMed ID: 19035177
[TBL] [Abstract][Full Text] [Related]
23. Have all-trans retinoic acid and arsenic trioxide replaced all-trans retinoic acid and anthracyclines in APL as standard of care.
Iland HJ; Wei A; Seymour JF
Best Pract Res Clin Haematol; 2014 Mar; 27(1):39-52. PubMed ID: 24907016
[TBL] [Abstract][Full Text] [Related]
24. Resistance to arsenic trioxide and retinoic acid therapy in acute promyelocytic leukemia.
Zhang X; Pan J
Ann Hematol; 2017 Apr; 96(4):707-708. PubMed ID: 28154895
[No Abstract] [Full Text] [Related]
25. Understanding the molecular pathogenesis of acute promyelocytic leukemia.
Lo-Coco F; Hasan SK
Best Pract Res Clin Haematol; 2014 Mar; 27(1):3-9. PubMed ID: 24907012
[TBL] [Abstract][Full Text] [Related]
26. Long term curative effects of sequential therapy with all-trans retinoic acid, arsenious oxide and chemotherapy on patients with acute promyelocytic leukemia.
Pei R; Cao J; Ma J; Zhang P; Liu X; Du X; Chen D; Sha K; Chen L; Li S; Wu J; Fan Z; Lin L; Ye P; Tang S; Zhang B
Hematology; 2012 Nov; 17(6):311-6. PubMed ID: 23168069
[TBL] [Abstract][Full Text] [Related]
27. Acute promyelocytic leukemia in childhood.
Gregory J; Feusner J
Curr Oncol Rep; 2009 Nov; 11(6):439-45. PubMed ID: 19840521
[TBL] [Abstract][Full Text] [Related]
28. Mutations of Epigenetic Modifier Genes as a Poor Prognostic Factor in Acute Promyelocytic Leukemia Under Treatment With All-Trans Retinoic Acid and Arsenic Trioxide.
Shen Y; Fu YK; Zhu YM; Lou YJ; Gu ZH; Shi JY; Chen B; Chen C; Zhu HH; Hu J; Zhao WL; Mi JQ; Chen L; Zhu HM; Shen ZX; Jin J; Wang ZY; Li JM; Chen Z; Chen SJ
EBioMedicine; 2015 Jun; 2(6):563-71. PubMed ID: 26285909
[TBL] [Abstract][Full Text] [Related]
29. Missense mutations in the PML/RARalpha ligand binding domain in ATRA-resistant As(2)O(3) sensitive relapsed acute promyelocytic leukemia.
Marasca R; Zucchini P; Galimberti S; Leonardi G; Vaccari P; Donelli A; Luppi M; Petrini M; Torelli G
Haematologica; 1999 Nov; 84(11):963-8. PubMed ID: 10553155
[TBL] [Abstract][Full Text] [Related]
30. [Therapeutic results with apl 93 protocol in acute promyelocytic leukemia (34 cases)].
Jeddi R; Hdiji S; Kacem K; Ben Lakhal R; Aissaoui L; Ben Abid H; Belhadj Ali Z; Meddeb B
Tunis Med; 2006 Nov; 84(11):717-20. PubMed ID: 17294898
[TBL] [Abstract][Full Text] [Related]
31. A novel clonal t(1;4)(p36.1;q31) translocation in acute promyelocytic leukaemia.
Zhang X; Pan J
J Clin Pathol; 2015 May; 68(5):391-3. PubMed ID: 25759405
[TBL] [Abstract][Full Text] [Related]
32. The expanding role of arsenic in acute promyelocytic leukemia.
Tallman MS
Semin Hematol; 2008 Jul; 45(3 Suppl 2):S25-9. PubMed ID: 18760708
[TBL] [Abstract][Full Text] [Related]
33. Secondary cytogenetic changes in acute promyelocytic leukemia--prognostic importance in patients treated with chemotherapy alone and association with the intron 3 breakpoint of the PML gene: a Cancer and Leukemia Group B study.
Slack JL; Arthur DC; Lawrence D; Mrózek K; Mayer RJ; Davey FR; Tantravahi R; Pettenati MJ; Bigner S; Carroll AJ; Rao KW; Schiffer CA; Bloomfield CD
J Clin Oncol; 1997 May; 15(5):1786-95. PubMed ID: 9164186
[TBL] [Abstract][Full Text] [Related]
34. Acute promyelocytic leukaemia and the t(15;17) translocation.
Gillard EF; Solomon E
Semin Cancer Biol; 1993 Dec; 4(6):359-67. PubMed ID: 8142621
[TBL] [Abstract][Full Text] [Related]
35. Acute promyelocytic leukemia with complex translocation t(5;17;15)(q35;q21;q22): case report and review of the literature.
Cho SR; Park SJ; Kim HJ; Park IJ; Choi JR; Jung HJ; Park JE
J Pediatr Hematol Oncol; 2011 Oct; 33(7):e326-9. PubMed ID: 21617563
[TBL] [Abstract][Full Text] [Related]
36. The genetics and clinical characteristics of children morphologically diagnosed as acute promyelocytic leukemia.
Zhao J; Liang JW; Xue HL; Shen SH; Chen J; Tang YJ; Yu LS; Liang HH; Gu LJ; Tang JY; Li BS
Leukemia; 2019 Jun; 33(6):1387-1399. PubMed ID: 30575821
[TBL] [Abstract][Full Text] [Related]
37. Acute promyelocytic leukaemia with a PML-RARA insertional translocation and a chromosome 21 abnormality in XYY syndrome: case report.
He Y; Li X; Wang D; Zhang E; Hu Y; Wang W; Huang R; Xiao R
J Int Med Res; 2014 Dec; 42(6):1363-73. PubMed ID: 25223426
[TBL] [Abstract][Full Text] [Related]
38. Combination therapy with arsenic trioxide, all-trans retinoic acid, and chemotherapy in acute promyelocytic leukemia patients with various relapse risks.
Huang H; Qin Y; Xu R; You X; Teng R; Yang L; Xu M; Liu H
Leuk Res; 2012 Jul; 36(7):841-5. PubMed ID: 22534100
[TBL] [Abstract][Full Text] [Related]
39. [Retinoic acid receptor alpha gene in t (15; 17) APL].
Takashima T; Misawa S
Nihon Rinsho; 1992 Jun; 50(6):1363-8. PubMed ID: 1325570
[TBL] [Abstract][Full Text] [Related]
40. Treatment of an acute promyelocytic leukemia relapse using arsenic trioxide and all-trans-retinoic in a 6-year-old child.
Rock N; Mattiello V; Judas C; Huezo-Diaz P; Bourquin JP; Gumy-Pause F; Ansari M
Pediatr Hematol Oncol; 2014 Mar; 31(2):143-8. PubMed ID: 24498972
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
